Jetema Co., Ltd.
Clinical trials sponsored by Jetema Co., Ltd., explained in plain language.
South Korean biopharmaceutical company specializing in botulinum toxin products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New wrinkle filler faces off against market leader Results expected Nov 2026 (estimated)
- New filler JTM102 takes on juvederm in Face-Off trial Results expected Dec 2026 (estimated)
-
New shot takes on botox for Post-Stroke arm tightness
Symptom relief CompletedThis early-stage trial tested a new drug called JTM201 against Botox in 30 adults who had a stroke at least 6 months ago and still have muscle stiffness in their arm. The goal was to see if JTM201 is safe and can reduce spasticity, making daily tasks like dressing and hygiene eas…
Phase 1 • Sponsor: Jetema Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
New filler takes on restylane for wrinkle correction
Symptom relief CompletedThis study tested a new dermal filler called UNIVELO Sub-Q against the well-known Restylane Sub-Q for temporarily smoothing deep smile lines (nasolabial folds). 65 adults with moderate to severe wrinkles received both fillers on opposite sides of their face. Researchers measured …
Sponsor: Jetema Co., Ltd. • Aim: Symptom relief
Last updated Jun 26, 2026 14:46 UTC